126 related articles for article (PubMed ID: 15958825)
1. Dose tailoring strategies in haemodialysis patients: a discussion of case histories.
Kleophas W
Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi31-6. PubMed ID: 15958825
[TBL] [Abstract][Full Text] [Related]
2. Once weekly treatment with epoetin-beta.
Locatelli F
Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi26-30. PubMed ID: 15958823
[TBL] [Abstract][Full Text] [Related]
3. Optimizing anaemia management with subcutaneous administration of epoetin.
Besarab A
Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi10-5. PubMed ID: 15958820
[TBL] [Abstract][Full Text] [Related]
4. Effect of switching from subcutaneous to intravenous administration of epoetin-alpha in haemodialysis patients: results from a Swedish multicentre survey.
Linde T; Furuland H; Wikström B
Scand J Urol Nephrol; 2005; 39(4):329-33. PubMed ID: 16118109
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
6. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
Leikis MJ; Kent AB; Becker GJ; McMahon LP
Nephrology (Carlton); 2004 Jun; 9(3):153-60. PubMed ID: 15189176
[TBL] [Abstract][Full Text] [Related]
7. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of once-weekly intravenous administration of epoetin-beta as a maintenance treatment for anemia in Japanese hemodialysis patients: a multicenter, open-label clinical study.
Shigematsu T; Takami H; Shimizu T; Shimoyama H; Kim S; Hirose S; Sakai T; Kono T; Mochizuki T; Nishio K; Degawa H; Motomiya Y
Ther Apher Dial; 2008 Dec; 12(6):469-74. PubMed ID: 19140845
[TBL] [Abstract][Full Text] [Related]
9. Dose of epoetin alfa used in haemodialysis patients when switching from subcutaneous to intravenous administration.
Pussell BA; Walker R
Nephrology (Carlton); 2007 Apr; 12(2):120-5. PubMed ID: 17371332
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
[TBL] [Abstract][Full Text] [Related]
12. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
Lee YK; Kim SG; Seo JW; Oh JE; Yoon JW; Koo JR; Kim HJ; Noh JW
Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
[TBL] [Abstract][Full Text] [Related]
13. Individualizing anaemia treatment: a discussion of case histories.
Muirhead N
Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi37-43. PubMed ID: 15958826
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin beta in peritoneal dialysis patients with chronic renal anaemia.
Grzeszczak W; Sulowicz W; Rutkowski B; de Vecchi AF; Scanziani R; Durand PY; Bajo A; Vargemezis V;
Nephrol Dial Transplant; 2005 May; 20(5):936-44. PubMed ID: 15769814
[TBL] [Abstract][Full Text] [Related]
15. Achieving therapeutic targets in renal anaemia: considering cost-efficacy.
Deray G
Curr Med Res Opin; 2004 Jul; 20(7):1095-101. PubMed ID: 15265254
[TBL] [Abstract][Full Text] [Related]
16. Once-every-2-weeks and once-weekly epoetin beta regimens: equivalency in hemodialyzed patients.
Mircescu G; Gârneată L; Ciocâlteu A; Golea O; Gherman-Căprioară M; Capsa D; Mota E; Gusbeth-Tatomir P; Ghenu A; Bălută S; Constantinovici N; Covic AC
Am J Kidney Dis; 2006 Sep; 48(3):445-55. PubMed ID: 16931218
[TBL] [Abstract][Full Text] [Related]
17. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years.
Jacobs C; Frei D; Perkins AC
Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii3-24. PubMed ID: 15824128
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous compared with intravenous epoetin treatment in patients on hemodialysis: one center study.
Malovrh M; Premru V
Ther Apher Dial; 2005 Jun; 9(3):233-6. PubMed ID: 15966996
[TBL] [Abstract][Full Text] [Related]
19. Once-weekly epoetin beta therapy in patients with solid tumours and chemotherapy-induced anaemia: a randomized, double-blind, dose-finding study.
Heras P; Kritikos K; Hatzopoulos A; Mitsibounas D
Eur J Cancer Care (Engl); 2008 Nov; 17(6):619-23. PubMed ID: 18707619
[TBL] [Abstract][Full Text] [Related]
20. Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin.
Hörl WH; Vanrenterghem Y; Canaud B; Mann J; Teatini U; Wanner C; Wikström B
Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii25-32. PubMed ID: 15824127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]